{"disease":{"id":"primary-progressive-multiple-sclerosis","name":"Primary progressive multiple sclerosis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ocrelizumab","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocrevus","generic_name":"OCRELIZUMAB","company_name":"Roche","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"CD20-directed Cytolytic Antibody [EPC]","quality_score":10,"revenue":"6500","mechanism":"Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process."},{"drug_id":"ocrevus","indication_name":"Primary progressive multiple sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ocrevus","company_name":"Kessler Foundation","drug_phase":"marketed","molecular_target":"B-lymphocyte antigen CD20","drug_class":"","quality_score":13,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05204459","title":"MS-ResearchBiomarkerS","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT00731692","title":"This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":970,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04458051","title":"Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":767,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05974839","title":"Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)","phase":"","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"State University of New York at Buffalo","has_results":false},{"nct_id":"NCT05974852","title":"Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS","phase":"","overall_status":"COMPLETED","enrollment_count":732,"lead_sponsor_name":"State University of New York at Buffalo","has_results":false},{"nct_id":"NCT04688788","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT02284568","title":"A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":374,"lead_sponsor_name":"Teva Branded Pharmaceutical Products R&D, Inc.","has_results":true},{"nct_id":"NCT07222618","title":"\"Selfie\" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05232825","title":"A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05663853","title":"An Observational Biomarker Study in Multiple Sclerosis (MS) Patients","phase":"","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"LAPIX Therapeutics Inc.","has_results":false},{"nct_id":"NCT03283826","title":"Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":134,"lead_sponsor_name":"Atara Biotherapeutics","has_results":false},{"nct_id":"NCT05893225","title":"Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT00950248","title":"Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT04705610","title":"Social Cognition in Multiple Sclerosis, From a Study of Eye Movement and Gaze Strategies Using Video-oculography","phase":"NA","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"Association de Recherche Bibliographique pour les Neurosciences","has_results":false},{"nct_id":"NCT07355387","title":"Home Based Functional Balance Intervention for Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Illinois at Chicago","has_results":false},{"nct_id":"NCT05359653","title":"Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03783416","title":"SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05496881","title":"Exercise Effects in Multiple Sclerosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"University of Regina","has_results":false},{"nct_id":"NCT02208050","title":"A Study of the Effectiveness of Fampridine in Improving Upper Limb Function in MS","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"University College Dublin","has_results":true},{"nct_id":"NCT05229861","title":"The Influence of HIIT Versus MCT on Cardiorespiratory Fitness in PPMS","phase":"NA","overall_status":"UNKNOWN","enrollment_count":61,"lead_sponsor_name":"Klinik Valens","has_results":false},{"nct_id":"NCT01854359","title":"Idebenone for Primary Progressive Multiple Sclerosis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT07483450","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05385731","title":"MUSCLE - Nordic Walking in MUltiple SCLErosis","phase":"NA","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Leonardo A. Peyré-Tartaruga","has_results":false},{"nct_id":"NCT01950234","title":"ACTH in Progressive Forms of MS","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":59,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT04918225","title":"Motor Asymmetry in Progressive Multiple Sclerosis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT06677710","title":"IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":34,"lead_sponsor_name":"Indapta Therapeutics, INC.","has_results":false},{"nct_id":"NCT05349474","title":"Metformin Treatment in Progressive Multiple Sclerosis","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT06436131","title":"The Effects of In-phase Bilateral Exercise in People with Progressive Multiple Sclerosis","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Cyprus University of Technology","has_results":false},{"nct_id":"NCT03493841","title":"Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Rebecca Spain","has_results":false},{"nct_id":"NCT04943289","title":"Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Joanne Kurtzberg, MD","has_results":false},{"nct_id":"NCT03562975","title":"Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University of South Florida","has_results":true},{"nct_id":"NCT06683612","title":"PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Contineum Therapeutics","has_results":false}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}